Consensus Guideline for Advanced Pancreatic Neuroendocrine Tumor.
- Author:
Heung Moon CHANG
1
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Review
- Keywords:
Pancreas;
Neuroendocrine tumor;
Chemotherapy;
Targeted agent
- MeSH:
Biology;
Cisplatin;
Consensus;
Drug Therapy, Combination;
Etoposide;
Humans;
Neuroectodermal Tumors, Primitive;
Neuroendocrine Tumors;
Pancreas;
Peptides;
Somatostatin
- From:Korean Journal of Medicine
2011;80(4):393-396
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The goals of medical treatment for advanced pancreatic neuroendocrine tumor (PNET) are to control hormone-related symptoms and to prolong overall survival. Somatostatin analogues have been used for decreasing the secretion of peptides and relieving symptoms. Recent studies showed that these agents also have an anti-tumor effect and could prolong the survival of patients with advanced PNET. For well-differentiated PNET, streptozocin-based combination chemotherapy has been used for a long time and recent several studies showed survival benefit of targeted agents including angiogenesis inhibitor and mTOR inhibitor. For poorly-differentiated tumors, the number of clinical studies is very limited and the combination of etoposide and cisplatin is widely used. Based on the recent progress in the understanding of tumor biology, newer targeted agents are tested and some of these agents showed promising activity.
